edrophonium has been researched along with Myasthenic Syndromes, Congenital in 3 studies
Edrophonium: A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles.
edrophonium : A quaternary ammonium ion that is N-ethyl-N,N-dimethylanilinium in which one of the meta positions is substituted by a hydroxy group. It is a reversible inhibitor of cholinesterase, with a rapid onset (30-60 seconds after injection) but a short duration of action (5-15 minutes). The chloride salt is used in myasthenia gravis both diagnostically and to distinguish between under- or over-treatment with other anticholinesterases. It has also been used for the reversal of neuromuscular blockade in anaesthesia, and for the management of poisoning due to tetrodotoxin, a neuromuscular blocking toxin found in puffer fish and other marine animals.
Myasthenic Syndromes, Congenital: A heterogeneous group of disorders characterized by a congenital defect in neuromuscular transmission at the NEUROMUSCULAR JUNCTION. This includes presynaptic, synaptic, and postsynaptic disorders (that are not of autoimmune origin). The majority of these diseases are caused by mutations of various subunits of the nicotinic acetylcholine receptor (RECEPTORS, NICOTINIC) on the postsynaptic surface of the junction. (From Arch Neurol 1999 Feb;56(2):163-7)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Most congenital myasthenic syndromes (CMS) have postsynaptic defects from mutations within the muscle acetylcholine receptor (AChR)." | 1.32 | Mutation in the AChR ion channel gate underlies a fast channel congenital myasthenic syndrome. ( Beeson, D; Brydson, M; Croxen, R; Newsom-Davis, J; Vincent, A; Webster, R, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ohkawara, B | 1 |
| Cabrera-Serrano, M | 1 |
| Nakata, T | 1 |
| Milone, M | 1 |
| Asai, N | 1 |
| Ito, K | 1 |
| Ito, M | 1 |
| Masuda, A | 1 |
| Ito, Y | 1 |
| Engel, AG | 1 |
| Ohno, K | 1 |
| Schara, U | 1 |
| Della Marina, A | 1 |
| Abicht, A | 1 |
| Webster, R | 1 |
| Brydson, M | 1 |
| Croxen, R | 1 |
| Newsom-Davis, J | 1 |
| Vincent, A | 1 |
| Beeson, D | 1 |
1 review available for edrophonium and Myasthenic Syndromes, Congenital
| Article | Year |
|---|---|
Congenital myasthenic syndromes: current diagnostic and therapeutic approaches.
Topics: Acetylcholinesterase; Adolescent; Biopsy; Child; Cholinesterase Inhibitors; Diagnosis, Differential; | 2012 |
2 other studies available for edrophonium and Myasthenic Syndromes, Congenital
| Article | Year |
|---|---|
LRP4 third β-propeller domain mutations cause novel congenital myasthenia by compromising agrin-mediated MuSK signaling in a position-specific manner.
Topics: Adolescent; Agrin; Animals; Base Sequence; beta Catenin; Cell Line; Chlorocebus aethiops; Cholinergi | 2014 |
Mutation in the AChR ion channel gate underlies a fast channel congenital myasthenic syndrome.
Topics: Adolescent; Amino Acid Sequence; Biopsy; Cell Line; DNA Mutational Analysis; Edrophonium; Electrodia | 2004 |